Preschoolers, children, adolescents, and adults with recurrent wheeze and moderate persistent asthma should be treated with daily inhaled corticosteroids, according to guidelines. Intermittent or as-needed inhaled corticosteroids therapy in response to symptoms, on the other hand, is a newer method. The purpose of the review was to compare this technique to the present daily-based treatment. 

Some writers have recently advocated for the use of inhaled corticosteroids based on symptoms. It has been proposed that a symptom-based strategy might reduce drug use, reduce the likelihood of adverse effects, and lower healthcare expenditures. In contrast, giving intermittent inhaled corticosteroids might provide the wrong message to patients about the disease’s chronicity. There is a substantial corpus of high-quality clinical research and systematic reviews that have addressed this crucial debate and whose analysis allows us to draw some key findings.

The available data do not support a shift towards an intermittent or symptom-based usage strategy for recurrent wheeze and mild-to-moderate persistent asthma. At this time, there is no compelling reason to change the present technique to inhaled corticosteroid administration, and further research comparing these two regimens is required.